Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune Inc (ALT) is a clinical-stage biopharmaceutical company pioneering peptide-based therapeutics for obesity, metabolic disorders, and liver diseases. This page serves as the definitive source for verified news and press releases directly from the company and trusted financial publications.
Investors and researchers will find timely updates on clinical trial progress, including developments for pemvidutide, the company’s GLP-1/glucagon dual receptor agonist candidate. Track regulatory milestones, partnership announcements, and strategic initiatives that shape Altimmune’s research pipeline.
Our curated news feed includes earnings reports, scientific presentations, and manufacturing updates, providing a holistic view of the company’s trajectory. All content is rigorously vetted to ensure alignment with financial reporting standards and clinical accuracy.
Bookmark this page for efficient access to Altimmune’s latest material events. Check regularly for updates on pivotal studies in metabolic-associated steatohepatitis (MASH) and obesity therapeutics, ensuring you stay informed on developments impacting this innovative biopharma leader.
Altimmune, Inc. (ALT) announced positive results from a 12-week Phase 1b study of pemvidutide for non-alcoholic fatty liver disease (NAFLD). All dosing groups (1.2 mg, 1.8 mg, 2.4 mg) achieved primary endpoints, with a 68.5% relative reduction in liver fat at the 1.8 mg dose. Subjects without diabetes saw a mean weight loss of 4.9% (placebo-adjusted 4.7%). The treatment was well-tolerated, mainly with mild gastrointestinal events, and no serious adverse events were reported. Next steps include data from a 24-week NAFLD trial and interim results from the MOMENTUM obesity trial.
Altimmune, Inc. (Nasdaq: ALT) reported its financial results for the second quarter of 2022, with a net loss of $20.1 million or $0.42 per share, an improvement from a net loss of $24.8 million in Q2 2021. The company reported minimal revenue due to the discontinuation of T-COVID and NasoShield programs. Altimmune is advancing its pemvidutide clinical trials, with topline data from a 12-week Phase 1b trial in subjects with obesity/overweight and non-alcoholic fatty liver disease (NAFLD) expected in mid-September 2022.
Research and development expenses increased to $16 million, primarily due to pemvidutide development.
Altimmune, Inc. (Nasdaq: ALT) will announce its second quarter 2022 financial results on August 11, 2022, followed by a conference call at 8:30 am E.T. to discuss these results and provide a business update. The call will be accessible via webcast on Altimmune's Investor Relations website. The company focuses on developing peptide-based therapeutics for obesity and liver diseases, with its lead candidate, pemvidutide, targeting obesity and NASH. Altimmune is also advancing its HepTcell™ immunotherapeutic for chronic hepatitis B.
Altimmune presented the results of its Phase 1 clinical trial for pemvidutide at the 2022 International Liver Congress, focusing on obesity and NASH treatment. The presentation, titled "Pemvidutide (ALT-801), a novel GLP-1/Glucagon Dual Receptor Agonist, Achieves Rapid and Potent Reductions in Body Weight and Liver Fat", was delivered by Dr. Stephen A. Harrison on June 25, 2022. The study displayed significant findings, earning a spot in the congress's Best of International Liver Congress. Additionally, Dr. Scott Harris will discuss study findings at a press conference on June 24, 2022.
Altimmune, Inc. (Nasdaq: ALT) announced its participation in two upcoming investor conferences in June 2022. The events include the Jefferies 2022 Global Healthcare Conference on June 10 at 10:00 am ET and the JMP Securities Life Sciences Conference on June 16 at 9:00 am ET, both held in New York. Interested investors can access the webcast via the company’s website. Altimmune develops novel therapeutics for obesity and liver diseases.
Altimmune, Inc. (Nasdaq: ALT) announced that Dr. Samuel Klein will present at the 82nd American Diabetes Association Scientific Sessions from June 3-7, 2022, in New Orleans, LA. He will discuss the results of a Phase 1 clinical trial for pemvidutide, a dual receptor agonist targeting obesity and NASH. The presentation is scheduled for June 6, 2022, at 4:30 pm CDT, highlighting pemvidutide's potential for significant weight loss without dose adjustments. Altimmune is committed to developing innovative peptide-based therapies for metabolic and liver diseases.
Altimmune, Inc. (Nasdaq: ALT) announced that Dr. Scott Harris will present at the 5th Global NASH Congress in London on May 27, 2022. His presentation will focus on pemvidutide, a novel dual receptor agonist aimed at treating obesity and NASH. Dr. Harris will also moderate a panel on clinical endpoints in NASH trials. The event highlights Altimmune's commitment to developing innovative therapeutics in the weight loss and liver disease sectors.
Altimmune, a clinical-stage biopharmaceutical company (Nasdaq: ALT), announced its participation in two investor conferences in May 2022. The H.C. Wainwright Global Investment Conference is set for May 24 at 7:00 am Eastern Time, available via webcast. The B. Riley Securities Institutional Investor Conference will take place on May 26 at 1:00 pm Pacific Time, featuring an in-person fireside chat. Altimmune focuses on developing novel therapeutics for obesity and liver diseases, including its lead candidate, pemvidutide (ALT-801).
Altimmune, Inc. (Nasdaq: ALT) reported financial results for Q1 2022, showcasing ongoing clinical developments of pemvidutide, a dual receptor agonist for obesity. Notably, interim data from the Phase 2 MOMENTUM trial is expected in Q4 2022, with 10% weight loss observed after 12 weeks. However, revenue was minimal at $0.0 million, down from $0.8 million YoY, primarily due to halted projects. R&D expenses rose to $15.1 million, leading to a net loss of $19.4 million. The company holds $180 million in cash, offering a healthy runway for future trials.
Altimmune, a clinical-stage biopharmaceutical company, will announce its first quarter 2022 financial results on May 12, 2022. The management will host a conference call at 8:30 AM ET to discuss these results and provide a business update. The company focuses on developing peptide-based therapeutics for obesity and liver diseases, with its primary candidate being pemvidutide (ALT-801) for obesity and NASH treatment. Additionally, it is developing HepTcell™, aimed at treating chronic hepatitis B.
FAQ
What is the current stock price of Altimmune (ALT)?
What is the market cap of Altimmune (ALT)?
